All In Biotech

Drug Trial Radar · NCT01883505

A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients

A Phase IIa Multicenter, Randomized, Double-blind, Placebo-controlled Study Followed by an Open-label Period, to Evaluate the Safety, Tolerability, and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Subcutaneous ND0612

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Jan 6, 2014

Primary completion

Apr 26, 2015

Study completion Apr 26, 2015

Sponsor

Lead sponsor
NeuroDerm Ltd.Industry
Sponsor type
Industry
First posted
Jun 21, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, placebo-controlled, double-blind, 2-period study evaluating the safety and pharmacokinetics (PK) of ND0612 in Parkinson's disease (PD) patients on an optimized oral levodopa (LD) regimen and experiencing ≥2 h/day of OFF time. Safety and tolerability, PK profile, pump usability, and the potential clinical effect of ND0612 will be explored in subjects with PD and motor fluctuations.

Conditions

  • Parkinson's Disease

Interventions

  • ND0612Drug

    Subcutaneous infusion via CRONO ND pump

  • PlaceboDrug

    Subcutaneous infusion via CRONO ND pump

  • EntacaponeDrug

    200 mg oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Dermal Rating Score: Draize ScoreTime frame: 14 days (Period 1)
  2. Maximum Dermal Rating Score: Erythema and Eschar FormationTime frame: 14 days (Period 1)
  3. Maximum Dermal Rating Score: EdemaTime frame: 14 days (Period 1)
  4. Maximum Dermal Rating Score: Presence of NodulesTime frame: 14 days (Period 1)
  5. Maximum Dermal Rating Score: PruritusTime frame: 14 days (Period 1)
  6. Maximum Dermal Rating Score: StainingTime frame: 14 days (Period 1)
  7. Maximum Dermal Rating Score: PainTime frame: 14 days (Period 1)
  8. Total Oral LD DoseTime frame: Day 15 (Period 1) and Day 22 (Period 2)
  9. LD CminTime frame: Day 15 (Period 1) and Day 22 (Period 2)
  10. LD CmaxTime frame: Day 15 (Period 1) and Day 22 (Period 2)
  11. LD AUC (0-10h)Time frame: Day 15 (Period 1) and Day 22 (Period 2)
  12. Time LD Concentration >1000 ng/mLTime frame: Day 15 (Period 1) and Day 22 (Period 2)
  13. LD Concentration FITime frame: Day 15 (Period 1) and Day 22 (Period 2)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Hadassah Medical Center

    Jerusalem, Israel

  • Rabin Medical Center

    Petah Tikva, Israel

  • Tel Aviv Medical Center

    Tel Aviv, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.